Retatrutide Heart Rate Increase: Trial Data

Retatrutide heart rate increase is a safety signal identified in Phase 2 clinical trial data for this investigational triple receptor agonist, which has no marketing authorisation in the UK or elsewhere. Retatrutide acts on GLP-1, GIP, and glucagon receptors simultaneously, and its glucagon component may contribute a more pronounced effect on heart rate than single or dual agonists. This article summarises what the trial data shows, why the effect occurs, who may be most affected, and what risks arise from seeking retatrutide outside an authorised clinical trial.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and can only be accessed within an authorised clinical trial. It is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[1] It is an investigational medicine being studied for the management of obesity and related metabolic conditions. Unlike tirzepatide (Mounjaro) or semaglutide (Wegovy, Ozempic), which have been authorised by the MHRA and recommended by NICE for specific indications, retatrutide remains at the clinical trial stage.^[2]

Retatrutide is a triple receptor agonist, meaning it acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[3][4] This triple mechanism distinguishes it from currently authorised dual or single agonists and is the basis for the research interest in its metabolic effects.

Because retatrutide is not authorised, it cannot be advertised, and no licensed supply route exists outside a clinical trial. Anyone who encounters it for sale online should be aware that such a product would not be a licensed medicine and may be falsified or unsafe. If you are interested in licensed weight-management treatments, your GP can discuss options that are currently available on the NHS or through regulated private services.

Did clinical trials find that retatrutide raises heart rate?

Yes, the 2023 Phase 2 trial found dose-dependent resting heart rate increases with retatrutide compared with placebo. The clinical significance is still being assessed in ongoing Phase 3 trials.

Yes, clinical trial data for retatrutide did identify increases in resting heart rate as a notable finding. In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants receiving retatrutide experienced mean increases in heart rate compared with placebo. The magnitude of the increase appeared to be dose-dependent, with higher doses associated with greater rises. The Phase 3 programme, which includes the TRIUMPH and TRANSCEND trials, is expected to provide more detailed characterisation of this effect across larger and more diverse populations.^[11]

The heart rate increases observed were generally described as modest in absolute terms, but they were consistent across dose groups and persisted over the treatment period studied. This pattern is not unique to retatrutide and has been observed with other medicines in the GLP-1 receptor agonist class, though the glucagon receptor component of retatrutide's mechanism may contribute an additional chronotropic effect.^[12][7]

It is important to note that these findings come from controlled trial settings with close monitoring. The clinical significance of the heart rate increases, particularly in people with pre-existing cardiovascular conditions, is one of the questions that ongoing and future trials are designed to address. No conclusions about individual risk can be drawn from trial-level data alone, and retatrutide remains investigational.

Why might GLP-1 based medicines cause your heart rate to go up?

GLP-1 receptors in cardiac tissue, including the sinoatrial node, have a positive chronotropic effect when activated. Retatrutide's additional glucagon receptor agonism may amplify this heart rate response.

GLP-1 receptor agonists can raise resting heart rate through a direct effect on the heart's electrical conduction system, as GLP-1 receptors are expressed in cardiac tissue, including the sinoatrial node, which sets the heart's natural rhythm. Activation of these receptors has a positive chronotropic effect, meaning it tends to increase the rate at which the heart beats. This is a pharmacological class effect rather than a sign of cardiac damage.

For retatrutide specifically, the glucagon receptor agonism adds a further dimension. Glucagon is known to have direct stimulatory effects on heart rate and cardiac contractility, and medicines that activate the glucagon receptor may therefore produce a more pronounced chronotropic response than GLP-1 single agonists alone.^[9][10] This is one reason why the heart rate signal in retatrutide trials has attracted particular attention from researchers and regulators.

The clinical relevance of a modest resting heart rate increase depends heavily on the individual. In most healthy adults, a small rise in resting heart rate is unlikely to cause symptoms or harm. However, in people with certain pre-existing heart conditions, arrhythmias, or those taking medicines that also affect heart rate, even a modest increase may warrant closer monitoring. These considerations are central to the safety assessments being conducted within the TRIUMPH and TRANSCEND trial programmes.

Who is most at risk from a raised heart rate during trials?

People with pre-existing arrhythmia, tachycardia, heart failure, or those taking rate-controlling medicines are at greatest risk. Phase 2 data excluded those with significant cardiovascular disease, limiting available evidence.

People with pre-existing cardiovascular conditions are the group most likely to require careful monitoring if a heart rate increase occurs during treatment with any investigational GLP-1 based medicine, including retatrutide. This includes individuals with a history of arrhythmia, tachycardia, heart failure, or ischaemic heart disease, as well as those taking medicines such as beta-blockers or other rate-controlling drugs, where an interaction with a chronotropic agent could complicate management.

In the Phase 2 retatrutide trial, participants with significant cardiovascular disease were generally excluded, which means the available data may not fully reflect the risk profile in people with complex cardiac histories.^[3][4] The TRIUMPH and TRANSCEND Phase 3 trials are designed with broader inclusion criteria and more detailed cardiovascular endpoints, which should provide clearer evidence about risk stratification.

People with thyroid conditions that already affect heart rate, such as hyperthyroidism, may also represent a group where additional caution is warranted, though this is a general clinical consideration rather than a specific finding from retatrutide trials. Because retatrutide is available only within authorised clinical trials, all participants undergo screening and monitoring protocols designed to identify and manage cardiovascular signals. Anyone with concerns about their cardiovascular health in the context of weight-management treatment should speak with their GP, who can advise on currently licensed options and appropriate monitoring.

What side effects and safety signals were reported in retatrutide studies?

The most common side effects were gastrointestinal, including nausea, vomiting, and diarrhoea, consistent with the GLP-1 class. Heart rate increase and injection site reactions were also reported safety signals.

The Phase 2 trial of retatrutide reported a side effect profile broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal effects being the most commonly reported. These included:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally more frequent at higher doses and tended to be most prominent during dose escalation, which is a pattern seen with other medicines in this class.^[14][15] Most gastrointestinal events were described as mild to moderate in severity.

Beyond gastrointestinal effects, the heart rate increase described in earlier sections was a notable safety signal. Injection site reactions were also reported, as is common with subcutaneously administered medicines. The UK SmPC for authorised GLP-1 medicines notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, and this is a class consideration that researchers monitor in retatrutide trials as well.^[16]

For authorised GLP-1 medicines, the MHRA's Yellow Card scheme allows patients and healthcare professionals to report suspected adverse reactions, and this applies to licensed products.^[17][18] For participants in a retatrutide clinical trial, adverse events should be reported to the trial team under the study protocol. The TRIUMPH and TRANSCEND Phase 3 programmes are collecting detailed safety data across larger populations, which will be essential for any future regulatory submission. No conclusions about the full safety profile of retatrutide can be drawn until that data is reviewed by regulators.

What are the risks of obtaining retatrutide outside a clinical trial?

Any retatrutide obtained outside an authorised trial is unlicensed and may be falsified, contaminated, or mislabelled. Risks include infection, unknown substances, and no medical supervision to manage adverse effects.

Obtaining retatrutide outside an authorised clinical trial carries serious risks, because any product sold or supplied under that name without regulatory authorisation is not a licensed medicine and may be falsified, contaminated, or mislabelled. Retatrutide has no UK marketing authorisation, and there is no legitimate commercial supply chain for it. Products encountered online or through unregulated channels claiming to be retatrutide cannot be verified for identity, purity, dose accuracy, or safety.

Using an unverified injectable product carries risks that go beyond the pharmacological effects of the intended medicine. These include infection at the injection site, systemic infection from non-sterile preparations, exposure to unknown substances, and the absence of any medical supervision to manage adverse effects. There is no way for a person using such a product to know what they are actually injecting.

From a regulatory standpoint, the MHRA takes a serious view of the supply of unlicensed medicines outside a clinical trial framework, and purchasing such products may also carry legal implications for the buyer.^[19][1] If you are concerned about your weight or metabolic health, your GP is the appropriate first point of contact. Licensed weight-management treatments exist and can be discussed in the context of your individual health history. If you believe you have been sold a falsified or unlicensed medicine, contact the MHRA directly. Do not attempt to self-manage any adverse effects from an unverified product at home; contact NHS 111 for urgent advice or attend your nearest A&E if you experience a life-threatening emergency.

Scientific References

1. No summer shortcut for safe weight loss.
2. GLP-1 medicines for weight loss and diabetes: what you need to know.
3. Triple–Hormone-Receptor Agonist Retatrutide for Obesity.
4. Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
5. Cardiovascular Effects of Incretin Receptor Agonists: Beyond Glycemic Control.
6. Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.
7. Glucagon-like peptide-1 increases heart rate by a direct chronotropic effect on pacemaker cells of the sinus node.
8. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
9. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase.
10. Mechanisms for the cardiovascular effects of glucagon-like peptide-1.
11. Retatrutide for the treatment of obesity, obstructive sleep apnoea and related conditions: the TRIUMPH and TRANSCEND Phase 3 programme.
12. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and meta-analysis.
13. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
14. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review.
15. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
16. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
17. Adverse reactions to drugs.
18. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
19. Supply unlicensed medicinal products (specials).

Frequently Asked Questions